122 related articles for article (PubMed ID: 29326690)
1. Identifying the Presence of Prostate Cancer in Individuals with PSA Levels <20 ng ml
Cosma G; McArdle SE; Reeder S; Foulds GA; Hood S; Khan M; Pockley AG
Front Immunol; 2017; 8():1771. PubMed ID: 29326690
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer: Early Detection and Assessing Clinical Risk Using Deep Machine Learning of High Dimensional Peripheral Blood Flow Cytometric Phenotyping Data.
Cosma G; McArdle SE; Foulds GA; Hood SP; Reeder S; Johnson C; Khan MA; Pockley AG
Front Immunol; 2021; 12():786828. PubMed ID: 34975879
[TBL] [Abstract][Full Text] [Related]
3. Identifying prostate cancer and its clinical risk in asymptomatic men using machine learning of high dimensional peripheral blood flow cytometric natural killer cell subset phenotyping data.
Hood SP; Cosma G; Foulds GA; Johnson C; Reeder S; McArdle SE; Khan MA; Pockley AG
Elife; 2020 Jul; 9():. PubMed ID: 32717179
[TBL] [Abstract][Full Text] [Related]
4. Ability of PSA-positive circulating macrophages to detect prostate cancer.
Herwig R; Horninger W; Rehder P; Klocker H; Ramoner R; Thurnher M; Pinggera GM; Gozzi C; Konwalinka G; Bartsch G
Prostate; 2005 Feb; 62(3):290-8. PubMed ID: 15389786
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic classification of human CD4+ T cell subsets and their differentiation.
Okada R; Kondo T; Matsuki F; Takata H; Takiguchi M
Int Immunol; 2008 Sep; 20(9):1189-99. PubMed ID: 18635582
[TBL] [Abstract][Full Text] [Related]
6. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features.
D'Arena G; Musto P; Cascavilla N; Di Giorgio G; Fusilli S; Zendoli F; Carotenuto M
Haematologica; 1998 Mar; 83(3):197-203. PubMed ID: 9573672
[TBL] [Abstract][Full Text] [Related]
8. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
9. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
[TBL] [Abstract][Full Text] [Related]
10. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a simplified dual-platform flow cytometric method for measurement of lymphocyte subsets and T-cell maturation phenotypes in the population of Nouna, Burkina Faso.
Böhler T; von Au M; Klose N; Müller K; Coulibaly B; Nauwelaers F; Spengler HP; Kynast-Wolf G; Kräusslich HG
Clin Vaccine Immunol; 2007 Jun; 14(6):775-81. PubMed ID: 17442847
[TBL] [Abstract][Full Text] [Related]
12. Peripheral blood T lymphocyte subsets in children with congenital asplenia.
Motkowski R; Michalkiewicz J; Mikoluc B; Smolka-Afifi D; Pietrucha B; Kubiszewska I; Piotrowska-Jastrzebska J; Bernatowska E
Hum Immunol; 2012 Nov; 73(11):1091-7. PubMed ID: 22902394
[TBL] [Abstract][Full Text] [Related]
13. Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction.
Djavan B; Remzi M; Zlotta AR; Seitz C; Wolfram R; Hruby S; Bursa B; Schulman CC; Marberger M
Tech Urol; 1999 Jun; 5(2):71-6. PubMed ID: 10458658
[TBL] [Abstract][Full Text] [Related]
14. Probability state modeling of memory CD8⁺ T-cell differentiation.
Inokuma MS; Maino VC; Bagwell CB
J Immunol Methods; 2013 Nov; 397(1-2):8-17. PubMed ID: 23954473
[TBL] [Abstract][Full Text] [Related]
15. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
17. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?
Khan MA; Carter HB; Epstein JI; Miller MC; Landis P; Walsh PW; Partin AW; Veltri RW
J Urol; 2003 Dec; 170(6 Pt 1):2274-8. PubMed ID: 14634395
[TBL] [Abstract][Full Text] [Related]
18. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
19. Polychromatic (eight-color) slide-based cytometry for the phenotyping of leukocyte, NK, and NKT subsets.
Mittag A; Lenz D; Gerstner AO; Sack U; Steinbrecher M; Koksch M; Raffael A; Bocsi J; Tárnok A
Cytometry A; 2005 Jun; 65(2):103-15. PubMed ID: 15830380
[TBL] [Abstract][Full Text] [Related]
20. CD8+CD45RA+CD27-CD28-T-cell subset in PBL of cervical cancer patients representing CD8+T-cells being able to recognize cervical cancer associated antigens provided by HPV 16 E7.
Pilch H; Hoehn H; Schmidt M; Steiner E; Tanner B; Seufert R; Maeurer M
Zentralbl Gynakol; 2002; 124(8-9):406-12. PubMed ID: 12655469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
